Merck & Co. stock: Jefferies conference set for November 19
Published on 11/15/2026 at 17:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMerck's investor week
- Merck will participate in the Jefferies 2026 Global Healthcare Conference in London on November 19.
- The company expects 2026 worldwide sales of 66.8 billion to 67.3 billion US dollars.
- Recent regulatory developments include positive EU CHMP opinions for ENFLONSIA and WELIREG.
Merck & Co. will participate in the Jefferies 2026 Global Healthcare Conference in London on Thursday, November 19, according to the company's investor relations calendar. The event is the main scheduled investor appointment for the week of November 16 through November 22.
Conference follows third-quarter update
Merck's latest financial release, published on October 29, reported third-quarter worldwide sales of 18.1 billion US dollars, up 5 percent from the prior-year quarter. GAAP earnings per share were 2.04 US dollars, while non-GAAP earnings per share were 2.49 US dollars; both figures included a one-time charge of 0.12 US dollars per share related to a global license agreement with SciBrunch.
The company raised the midpoint of its full-year 2026 sales outlook and now expects worldwide sales between 66.8 billion and 67.3 billion US dollars. It also expects full-year non-GAAP earnings per share between 2.77 and 2.82 US dollars. The third-quarter release identifies the outlook as including one-time charges tied to the Cidara and Terns acquisitions and the SciBrunch agreement.
Regulatory momentum remains relevant
Merck's investor relations page also lists two positive European Committee for Medicinal Products for Human Use opinions dated November 13, covering ENFLONSIA and WELIREG. Those developments add a regulatory backdrop to the London conference, while the third-quarter figures show the scale of the business that investors will assess.
Merck & Co. stock traded at 133.37 euros on Lang & Schwarz at 17:45:36 CET on Sunday, November 15. The quote is shown without a daily comparison.
Merck & Co. investor facts
- Company: Merck & Co.
- ISIN: US58933Y1055
- Trading venue: Lang & Schwarz
- Price: 133.37 euros on November 15, 2026 at 17:45:36 CET
- Upcoming event: Jefferies 2026 Global Healthcare Conference, November 19, 2026
- Third-quarter 2026 sales: 18.1 billion US dollars
- Full-year 2026 sales outlook: 66.8 billion to 67.3 billion US dollars
For broader US market context, see current S&P 500 market reports.
